【“减肥神药”对决：礼来的Zepbound力压诺和诺德的Wegovy】金十数据12月4日讯，礼来公司表示，在两款重磅减肥药物的首次对照试验中，该公司的减肥药物Zepbound的表现优于诺和诺德公司的Wegovy（诺和盈）。在一项由礼来公司资助的研究中，服用Zepbound的受试者在72周内平均减重20%——约50磅，而服用Wegovy的受试者减重14%。这一结果证实了之前对这两种药物进行的试验，这些试验表明Zepbound的效果更强。两种药物的副作用主要与胃肠道有关，并且相似。礼来表示，完整的研究结果将发表在同行评审期刊上，并将于明年在医学会议上公布。在哥本哈根，诺和诺德的股价一度下跌1.8%，今年以来上涨了约11%。礼来(LLY.N)的股价在美股开盘前上涨了2%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.